Search
Home
Products
Voglibose
Voglibose WeChat WhatsApp
Product Name Voglibose
Price: $77 / 20mg
Catalog No.: CN06370
CAS No.: 83480-29-9
Molecular Formula: C10H21NO7
Molecular Weight: 267.3 g/mol
Purity: >=98%
Type of Compound: Miscellaneous
Physical Desc.: Powder
Source:
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
SMILES: OCC(N[C@H]1C[C@](O)(CO)[C@H]([C@@H]([C@H]1O)O)O)CO
Contact us
First Name:
Last Name:
E-mail:
Question:
Description Voglibose is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.Target: α-glucosidasesglibose can inhibit the intestinal α-glucosidases, which are responsible for the digestion of disaccharides such as maltose and sucrose, including maltase and sucrase. The Ki values of Voglibose for sucrase and maltase are about 106and 105 times smaller than the Km values for sucrose and maltose [1]. Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats [2]. Voglibose (0.001%) treatment increases GLP-1 secretion (Voglibose alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (Voglibose alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. Voglibose (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. Voglibose (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice [3].
Density1.6±0.1 g/cm3
Boiling Point601.9±55.0 °C at 760 mmHg
Flash Point274.1±22.1 °C
Exact Mass267.131805
PSA153.64000
LogP-2.36
Vapour Pressure0.0±3.9 mmHg at 25°C
Storage conditionStore at -20°C